US2020230224A1PendingUtilityA1

Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development

49
Assignee: UNIV NORTH CAROLINA CHAPEL HILLPriority: Nov 2, 2014Filed: Aug 29, 2019Published: Jul 23, 2020
Est. expiryNov 2, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Inventors:Ralph BaricDouglas WidmanBoyd YountEmily GallichotteScott RoyalAravinda DesilvaJesica Swanstrom
C07K 16/1145Y02A50/30C12N 2770/24171A61K 39/12G01N 33/56983C12N 2770/24134G01N 2469/20C07K 2317/21G01N 2333/18C07K 2319/40C12N 2770/24122C07K 14/005A61K 2039/5258C12N 2770/24123A61K 2039/575G01N 2333/185C12N 7/00A61P 31/14Y02A50/53C07K 16/1063Y02A50/386
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone that comprises amino acid substitutions that introduce an epitope that is recognized by an antibody that is reactive with a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone, wherein the dengue virus E glycoprotein backbone is from dengue virus serotype 4 and the antibody is reactive with dengue virus serotype 3.

Join the waitlist — get patent alerts

Track US2020230224A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.